Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy.

ABSTRACT:

Background

Epigenetic silencing of O(6)-methylguanine-DNA-methyltransferase (MGMT) by promoter methylation is associated with improved survival in glioblastomas treated with alkylating agents. In this study, we investigated MGMT promoter methylation in glioblastomas treated with temozolomide and radiotherapy in a single UK treatment centre.

Methods

Quantitative methylation data at individual CpG sites were obtained by pyrosequencing for 109 glioblastomas.

Results

Median overall survival (OS) was 12.4 months with 2-year survival of 17.9%. Pyrosequencing data were reproducible with archival samples yielding data for all glioblastomas. Variation in methylation patterns of discrete CpG sites and intratumoral methylation heterogeneity were observed. A total of 58 out of 10

SUBMITTER: Dunn J 

PROVIDER: S-EPMC2713697 | biostudies-literature | 2009 Jul

REPOSITORIES: biostudies-literature